IMNN
Imunon, Inc.·Healthcare
2.20
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $2.0852W H: $41.22
IMNN NEWS
seekingalpha.com
May 12
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
globenewswire.com
May 12
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.
globenewswire.com
May 5
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m.
seekingalpha.com
Mar 31
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 31
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J.
globenewswire.com
Mar 25
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT).
